Dynavax Technologies (LTS:0IDA) Current Accrued Expense : $49.0 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dynavax Technologies Current Accrued Expense?

Dynavax Technologies's Current Accrued Expense for the quarter that ended in Mar. 2024 was $49.0 Mil.

Dynavax Technologies's quarterly Current Accrued Expense increased from Sep. 2023 ($46.8 Mil) to Dec. 2023 ($52.4 Mil) but then declined from Dec. 2023 ($52.4 Mil) to Mar. 2024 ($49.0 Mil).

Dynavax Technologies's annual Current Accrued Expense declined from Dec. 2021 ($183.3 Mil) to Dec. 2022 ($143.2 Mil) and declined from Dec. 2022 ($143.2 Mil) to Dec. 2023 ($52.4 Mil).

Dynavax Technologies Current Accrued Expense Historical Data

The historical data trend for Dynavax Technologies's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Current Accrued Expense Chart

Dynavax Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

18.92

21.90

183.33

143.23

52.43

Dynavax Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															80.39	37.47	46.75	52.43	48.98

Dynavax Technologies Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Dynavax Technologies Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (LTS:0IDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (LTS:0IDA) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

DVAX:USA DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (LTS:0IDA) Headlines

No Headlines